Please ensure Javascript is enabled for purposes of website accessibility

Why Amicus Therapeutics Shares Are Crashing 21.8% Today

By Todd Campbell – Nov 29, 2016 at 1:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A longer than hoped pathway to commercialization in the United States is disappointing investors.

Image source: Getty Images.

What happened 

After announcing that a new trial will be necessary before it can file for FDA approval of its Fabry disease drug, shares of Amicus Therapeutics (FOLD 0.18%) are tumbling 21.8% at 12:00 p.m. EST Tuesday.

So what 

Amicus Therapeutics already markets its Fabry disease drug -- Galafold -- in Europe, and until now it had hoped that the FDA would consider approving Galafold without requiring additional studies. Unfortunately, management disclosed after the bell Monday night that U.S. regulators will require more evidence before issuing a green light.

Management plans to initiate a trial to collect data on gastrointestinal symptoms in Galafold patients in 2017 and trial data should be available in 2019. Based on that timeline, the earliest Galafold is likely to win approval for use in the U.S. is likely 2020.

Now what

Fabry disease is a progressive disease that can negatively impact the kidneys. Currently, patients are treated with infusions of enzyme replacement therapies that can cost hundreds of thousands of dollars per year. In Europe, Shire sells the ERT Replagel and in the U.S. and Europe Sanofi markets the ERT Fabrazyme. Last quarter, Replagel and Fabrazyme's sales totaled $118.9 million and $187 million, respectively.

Amicus Therapeutics entered this market earlier this year when EU regulators approved Galafold for use in its member countries. Galafold, an oral therapy that can help a subset of Fabry disease patients who still produce limited amounts of the enzyme causing this disease, has secured reimbursement in five EU member countries. In the third quarter, Galafold's sales were $2.3 million.

Galafold's sales should continue building as deals are inked in more EU member countries, but sales may not grow fast enough to make the company profitable anytime soon. Management expects expenses will cause them to burn through at least $135 million in net cash this year.

Clearly, a sooner-rather-than-later approval in the U.S. could have improved that burn rate, but investors might not want to dismiss the company outright on this news. Fabry disease is rare, but it's still an important indication that offers nine-figure peak sales potential outside of America. Management believes that Galafold's EU approval allows them to target roughly two-thirds of the global Fabry disease market.

Todd Campbell owns shares of Amicus Therapeutics. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. Like this article? Follow him on Twitter where he goes by the handle @ebcapital to see more articles like this.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amicus Therapeutics Stock Quote
Amicus Therapeutics
$10.87 (0.18%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.